For example, clinical trials combining IFN-α with pembrolizumab in melanoma patients have demonstrated improved response rates compared to pembrolizumab monotherapy, indicating the potential of IFN-α to augment the immune system to recognize and destroy tumor cells. Here, IFNA1 is linked to neoplasm.